A case report on the first confirmed case of PNH in Ethiopia

PNH

Authors

  • Dr Yidnekachew Asrat Addis Ababa university
  • Dr Seifu Kebede Addis Ababa university
  • Dr Amha Gebremedhin Addis Ababa university
  • Dr Abdulaziz Abubeker Addis Ababa university
  • Dr Fisehatsion Tadese Addis Ababa university
  • Dr Fozia Abdela Addis Ababa university

Keywords:

PNH paroxysmal nocturnal hemoglobinuria

Abstract

  1. PNH is an acquired hemolytic disorder caused by somatic mutation characterized by intravascular hemolysis with pancytopenia and a tendency to thrombosis. It is a rare disease with incidence of 1 to 10 cases per million populations. We are reporting the first confirmed case of PNH in Ethiopia. He is a 38 years old man who presented with anemia and jaundice of 3 years duration; he has mild pallor; lab examinations showed moderate anemia with features of coomb’s negative intravascular hemolysis; and finally very large clone of PNH cells on immunophenotypic analysis

Author Biographies

Dr Yidnekachew Asrat, Addis Ababa university

MD,  Internal medicine resident at Addis Ababa university 

Dr Seifu Kebede, Addis Ababa university

  1. MD, Assistant professor of internal medicine and hematology at Addis Ababa university, school of medicine, department of Internal medicine 

Dr Amha Gebremedhin, Addis Ababa university

MD,  associate professor of internal medicine and hematology at Addis Ababa university, school of medicine,  department of internal medicine

Dr Abdulaziz Abubeker , Addis Ababa university

MD, Assistant professor of internal medicine and hematology at Addis Ababa university, school of medicine, department of Internal medicine

Dr Fisehatsion Tadese, Addis Ababa university

MD, Assistant professor of internal medicine and hematology at Addis Ababa university, school of medicine, department of Internal medicine

Dr Fozia Abdela, Addis Ababa university

MD, Assistant professor of internal medicine, Hematology fellow at Addis Ababa university, school of medicine, department of Internal medicine

References

References
Luzzatto L, Bessler M, Rotoli B: Somatic mutations in paroxysmal nocturnal hemoglobinuria: a blessing in disguise? Cell. 1997; 88(1): 1–4
Screzenmeir H, Muus P, Socie G, et al. Baseline characteristics and disease burden in patients in the International Paroxysmal Nocturnal Hemoglobinuria Registry. Hematologica 2014; 99:922
Parker C, Omine M, Richards S, et al. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood 2005; 106: 3699-3709.
Fletcher M, Sutherland DR, Whitby L, et al. Standardizing Leucocyte PNH clone detection: An international study. Cytometry B Clin Cytom 2014.
Hillmen P, Lewis SM, Bessler M, Luzzatto L, Dacie JV. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med 1995; 333: 1253-58.
S. Hussain, A. Qureshi, J. Kazi: Renal involvement in paroxysmal nocturnal hemoglobinuria. Nephron Clin Pract 2013; 123:28–35

Garrick Laudin, Lizemarie Wium: A case of paroxysmal nocturnal hemoglobinuria (PNH) in an obstetric patient: A South African perspective. CMI 2019; 13(1)
Issaragrisil S, Piankijagum A, Tang-naitrisorana Y: Corticosteroids therapy in paroxysmal nocturnal hemoglobinuria. Am J Hematol 1987; 25: 77-83
McKeage K: Eculizumab: a review of its use in paroxysmal nocturnal haemoglobinuria. Drugs. 2011; 71(17): 2327–45.
Dinerstein C. Why Is Soliris the Most Expensive Drug In The US? American Council in Science and Health. May 27, 2017.

Downloads

Published

2020-12-31

Issue

Vol. 59 No. 01 (2021): EMJ January 2021 issue

Section

Case Report